利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

205 条记录 (耗时 0.052 秒)

    SSX-2 peptide analogs
    13.
    发明申请
    SSX-2 peptide analogs 有权
    SSX-2肽类似物

    公开(公告)号：US20060063913A1

    公开(公告)日：2006-03-23

    申请号：US11156253

    申请日：2005-06-17

    申请人： Liping Liu ,  Zhidong Xie ,  David Diamond

    发明人： Liping Liu ,  Zhidong Xie ,  David Diamond

    IPC分类号： C07K14/70

    CPC分类号： C07K7/06 ,  A61K38/00 ,  C07K14/4748

    摘要： Some embodiments relate to analogs of peptides corresponding to class I MHC-restricted T cell epitopes and methods for their generation. These analogs can contain amino acid substitutions at residues that directly interact with MHC molecules, and can confer improved, modified or useful immunologic properties. Additionally classes of analogs, in which the various substitutions comprise the non-standard residues norleucine and/or norvaline, are disclosed.

    摘要翻译： 一些实施方案涉及对应于I类MHC限制性T细胞表位的肽类似物及其产生方法。 这些类似物可以在与MHC分子直接相互作用的残基处含有氨基酸取代，并且可以赋予改进的，修饰的或有用的免疫学特性。 公开了其中各种取代包含非标准残基正亮氨酸和/或正缬氨酸的类似物类别。

    Implantable cells that alleviate chronic pain in humans
    16.
    发明授权
    Implantable cells that alleviate chronic pain in humans 失效
    可减轻人体慢性疼痛的植入式细胞

    公开(公告)号：US5656267A

    公开(公告)日：1997-08-12

    申请号：US379790

    申请日：1995-01-27

    申请人： Jacqueline Sagen ,  George Demetrios Pappas

    发明人： Jacqueline Sagen ,  George Demetrios Pappas

    IPC分类号： A61K35/12 ,  A61K35/22 ,  A61K35/30 ,  A61K38/00 ,  A61K48/00 ,  C07K14/665 ,  C07K14/70 ,  C12N15/00 ,  A61F2/66

    CPC分类号： A61K38/13 ,  A61K35/22 ,  A61K35/30 ,  C07K14/665 ,  C07K14/70 ,  A61K48/00

    摘要： This invention provides a method of alleviating chronic pain in humans. Viable, implantable cells are selected which release neuroactive substances that reduce chronic pain. The cells are cultured to improve their viability, and administered into a region of the central nervous system of a patient who is suffering from chronic pain. The cells continue to secrete the neuroactive substances within the patient without exogenous stimulation. Suitable implantable cells include adrenal medullary tissue cells, chromaffin cells or genetically engineered cells.

    摘要翻译： 本发明提供减轻人体慢性疼痛的方法。 选择可行的可植入细胞，其释放减少慢性疼痛的神经活性物质。 培养细胞以改善其活力，并施用于患有慢性疼痛的患者的中枢神经系统的区域。 细胞继续分泌患者内的神经活性物质，无需外源刺激。 合适的可植入细胞包括肾上腺髓质组织细胞，嗜铬细胞或遗传工程细胞。

    Redox carriers for brain-specific drug delivery
    18.
    发明授权
    Redox carriers for brain-specific drug delivery 失效
    用于脑特异性药物递送的氧化还原载体

    公开(公告)号：US5389623A

    公开(公告)日：1995-02-14

    申请号：US766528

    申请日：1991-09-27

    申请人： Nicholas S. Bodor

    发明人： Nicholas S. Bodor

    IPC分类号： A61K38/00 ,  C07D209/32 ,  C07D211/90 ,  C07D213/80 ,  C07D213/82 ,  C07D401/12 ,  C07J43/00 ,  C07J71/00 ,  C07K5/078 ,  C07K5/097 ,  C07K14/70 ,  A61K31/56 ,  A61K31/455

    CPC分类号： C07D213/80 ,  A61K47/48161 ,  C07D209/32 ,  C07D211/90 ,  C07D213/82 ,  C07D401/12 ,  C07J43/003 ,  C07J71/0031 ,  C07K14/70 ,  C07K5/06139 ,  C07K5/0821 ,  A61K38/00

    摘要： Compounds of the formula ##STR1## and the nontoxic pharmaceutically acceptable salt thereof, wherein D is the residue of a centrally acting drug containing at least one reactive functional group selected from the group consisting of amino, hydroxyl, mercapto, carboxyl, amide and imide, said residue being characterized by the absence of a hydrogen atom from at least one of said reactive functional groups in said drug; n is a positive integer equal to the number of said functional groups from which a hydrogen atom is absent; and [DHC] is the reduced, biooxidizable, blood-brain barrier penetrating lipoidal form of a dihydropyridine.revreaction.pyridinium salt redox carrier, said carrier comprising a bivalent radical of the formula ##STR2## wherein the alkylene group can be straight or branched and can contain 1 to 3 carbon atoms; R.sub.o is a radical identical to the corresponding portion of a natural amino acid; and p is 1 or 2, provided that, when p is 2, then the alkylene groups can be the same or different and the R.sub.o radicals can be the same or different; said bivalent radical being so positioned that the terminal carbonyl function of the bivalent radical is linked to the drug residue while the terminal amino function of the bivalent radical is linked to the remaining portion of the carrier moiety; are adapted for the site-specific/sustained delivery of centrally acting drugs to the brain. The corresponding pyridinium salt type drug/carrier entities D --QC.sup.+ ].sub.n qY.sup.-t are also disclosed.

    摘要翻译： 式D [DHC] n（I）的化合物及其无毒的药学上可接受的盐，其中D是含有至少一个选自氨基，羟基，巯基，羧基的反应性官能团的中心作用药物的残基 ，酰胺和酰亚胺，所述残基的特征在于所述药物中至少一个所述反应性官能团不存在氢原子; n是与不存在氢原子的所述官能团的数目相等的正整数; 和[DHC]是还原的，可生物氧化的，血脑屏障穿透的二氢吡啶 - >β-吡啶鎓盐氧化还原载体的脂质形式，所述载体包含式“IMAGE”的二价基团，其中亚烷基可以是直链或支链的 并且可以含有1至3个碳原子; Ro是与天然氨基酸的相应部分相同的基团; p为1或2，条件是当p为2时，亚烷基可以相同或不同，且R f基团可以相同或不同; 所述二价基团的定位使得二价基团的末端羰基官能团与药物残基连接，而二价基团的末端氨基官能团与载体部分的剩余部分连接; 适用于中枢作用药物对大脑的特异性/持续递送。 还公开了相应的吡啶鎓盐型药物/载体实体D-QC +] n qY-t。

    Brain-specific drug delivery
    20.
    发明授权
    Brain-specific drug delivery 失效
    脑特异性药物递送

    公开(公告)号：US5187158A

    公开(公告)日：1993-02-16

    申请号：US639283

    申请日：1991-01-10

    申请人： Nicholas S. Bodor

    发明人： Nicholas S. Bodor

    IPC分类号： A61K38/00 ,  C07D209/32 ,  C07D211/90 ,  C07D213/80 ,  C07D213/82 ,  C07D401/12 ,  C07J43/00 ,  C07K14/70

    CPC分类号： C07D213/80 ,  A61K47/48161 ,  C07D209/32 ,  C07D211/90 ,  C07D213/82 ,  C07D401/12 ,  C07J43/003 ,  C07K14/70 ,  A61K38/00

    摘要： The subject compounds, which are adapted for the site-specific/sustained delivery of centrally acting drug species to the brain, are:(a) compounds of the formula[D-DHC] (I) wherein [D] is a centrally acting drug species, and [DHC] is the reduced, biooxidizable, blood-brain barrier penetrating lipoidal form of a dihydropyridine .revreaction. pyridinium salt redox carrier, with the proviso that when [DHC] is ##STR1## wherein R is lower alkyl or benzyl and [D] is a drug species containing a single NH.sub.2 or OH functional group, the single OH group when present being a primary or secondary OH group, said drug species being linked directly through said NH.sub.2 or OH functional group to the carbonyl function of [DHC], then [D] must be other than a sympathetic stimulant, steroid sex hormone or long chain alkanol; and(b) non-toxic pharmaceutically acceptable salts of compounds of formula (I) wherein [D] is a centrally acting drug species and [DHC] is the reduced, biooxidizable, blood-brain barrier penetrating lipoidal form of a dihydropyridine .revreaction. pyridinium salt redox carrier. The corresponding ionic pyridinium salt type drug/carrier entities [D-QC].sup.+ X.sup.- are also disclosed.

    摘要翻译： 适用于中枢作用药物物种向大脑的位点特异性/持续递送的主题化合物是：（a）式[D-DHC]（I）化合物，其中[D]为中枢作用药物 物种和[DHC]是二氢吡啶 - >β-吡啶鎓盐氧化还原载体的减少的，生物可氧化的血脑屏障穿透脂质形式，条件是当[DHC]为[IMAGE]，其中R为低级烷基或苄基 和[D]是含有单个NH 2或OH官能团的药物，当存在的单个OH基团是伯或仲OH基团时，所述药物物质通过所述NH 2或OH官能团直接连接到[ DHC]，则[D]必须不是交感兴奋剂，类固醇性激素或长链烷醇; 和（b）式（I）化合物的无毒的药学上可接受的盐，其中[D]是中心作用的药物物质，[DHC]是还原的，可生物氧化的，血脑屏障穿透的二氢吡啶 - - 吡啶鎓盐氧化还原载体。 还公开了相应的离子型吡啶鎓盐型药物/载体实体[D-QC] + X-。